Chao Ma1, Anren Kuang, Jiawei Xie. 1. Department of Nuclear Medicine, Affiliated Hospital of Medical College Qingdao University, Jiangsu Road 16, Qingdao, Shandong Province, China, 266003. machaopony@hotmail.com
Abstract
BACKGROUND: Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases has been observed in follow-up studies. The management of this condition remains controversial. Most studies support blind radioactive iodine treatment while others negate this approach. OBJECTIVES: To assess the effects of radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. SEARCH STRATEGY: Studies were obtained from computerised searches of MEDLINE, EMBASE, The Cochrane Library, China National Infrastructure (CNKI) and paper collections of conferences held in Chinese. SELECTION CRITERIA: Randomised controlled clinical trials and prospective controlled clinical trials. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and interviewed authors of all potentially relevant studies by electronic mail to verify randomisation procedures. One author entered data into a data extraction form and the second one verified the results of this procedure. MAIN RESULTS: Because of the absence of any suitable randomised or prospective controlled trial in this area, results currently cannot be presented. AUTHORS' CONCLUSIONS: The currently available evidence is insufficient to reliably assess the potential of radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.
BACKGROUND: Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases has been observed in follow-up studies. The management of this condition remains controversial. Most studies support blind radioactive iodine treatment while others negate this approach. OBJECTIVES: To assess the effects of radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. SEARCH STRATEGY: Studies were obtained from computerised searches of MEDLINE, EMBASE, The Cochrane Library, China National Infrastructure (CNKI) and paper collections of conferences held in Chinese. SELECTION CRITERIA: Randomised controlled clinical trials and prospective controlled clinical trials. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and interviewed authors of all potentially relevant studies by electronic mail to verify randomisation procedures. One author entered data into a data extraction form and the second one verified the results of this procedure. MAIN RESULTS: Because of the absence of any suitable randomised or prospective controlled trial in this area, results currently cannot be presented. AUTHORS' CONCLUSIONS: The currently available evidence is insufficient to reliably assess the potential of radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.
Authors: S A Hundahl; B Cady; M P Cunningham; E Mazzaferri; R F McKee; J Rosai; J P Shah; A M Fremgen; A K Stewart; S Hölzer Journal: Cancer Date: 2000-07-01 Impact factor: 6.860
Authors: K M van Tol; P L Jager; E G E de Vries; D A Piers; H M Boezen; W J Sluiter; R P F Dullaart; T P Links Journal: Eur J Endocrinol Date: 2003-06 Impact factor: 6.664
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Gauri R Khorjekar; Douglas Van Nostrand; Carlos Garcia; Jeffrey O'Neil; Shari Moreau; Francis B Atkins; Mihriye Mete; Michael H Orquiza; Kenneth Burman; Leonard Wartofsky Journal: Thyroid Date: 2014-06-20 Impact factor: 6.568
Authors: José F Carrillo; Rafael Vázquez-Romo; Margarita C Ramírez-Ortega; Liliana C Carrillo; Edgar Gómez-Argumosa; Luis F Oñate-Ocaña Journal: Front Endocrinol (Lausanne) Date: 2019-10-29 Impact factor: 5.555